Not for IM inj. Epidural or spinal hematomas resulting in long-term or permanent paralysis in associated use w/ spinal/epidural anesth or spinal puncture; or at higher risk w/ use of post-op indwelling epidural catheters, additional drugs affecting hemostasis (eg, NSAIDs), w/ traumatic or repeated epidural or spinal puncture, history of spinal surgery or deformity. Patients w/ increased risk of hemorrhage, eg, bacterial endocarditis, congenital or acquired bleeding disorders, active ulcerative & angiodysplastic GI disease, hemorrhagic stroke, post-brain, spinal or ophth surgery, or concomitant treatment w/ platelet inhibitors. Potentially fatal, major hemorrhages including retroperitoneal & intracranial bleeding. Bleeding at any site may occur; search for bleeding site if fall in hematocrit or BP occurs. Minimize risk of bleeding in percutaneous coronary revascularization procedures by adhering to recommended dosing intervals; achieve hemostasis at puncture site; immediately remove sheath if closure device is used; or remove sheath 6 hr after last inj if manual compression is used. Give next scheduled doses not sooner than 6-8 hr after sheath removal if treatment should be continued. Observe signs of bleeding & hematoma formation at the site of procedure. Patients w/ bleeding diathesis, uncontrolled arterial HTN, history of recent GI ulceration, diabetic retinopathy, renal dysfunction & hemorrhage. Use w/ extreme caution in patients w/ history of heparin-induced thrombocytopenia. Thrombocytopenia may occur. Do not use interchangeably w/ heparin or other LMWH. Recommend complete blood counts including platelet count & stool occult blood tests during treatment. May use antifactor Xa levels to monitor patients w/ significant renal impairment or during therapy if abnormal coagulation parameters or bleeding occur. Renal impairment; recommend dosage adjustment in severe renal impairment (CrCl <30 mL/min). Development of hyperkalemia is associated w/ patients w/ renal failure. Hepatic impairment. Do not use during pregnancy & lactation. Pregnant women w/ mechanical prosthetic heart valves. Elderly who may show delayed enoxaparin elimination; monitor elderly w/ low body wt; consider those predisposed to decreased renal function. Adjust dosage in preventive therapy & measure anti-Xa activity in curative therapy for the elderly. Not recommended in childn. Low wt patients (ie, <45 kg in women & <57 kg in men).